Galderma's Mirvaso wins FDA nod to reduce rosacea redness

The FDA granted approval on 26 August to Galderma Laboratories' topical gel product Mirvaso (brimonidine) as a once-daily treatment for adults 18 years or older to reduce the redness of rosacea, also known as facial erythema.

The FDA granted approval on 26 August to Galderma Laboratories' topical gel product Mirvaso (brimonidine) as a once-daily treatment for adults 18 years or older to reduce the redness of rosacea, also known as facial erythema.

Rosacea, which affects an estimated 16 million Americans, is a chronic, inflammatory and vascular disorder affecting the face. Redness, visible...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Dermatological

More from Therapy Areas

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By 

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By 

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By 

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.